Pyridinylimidazole inhibitors of Tie2 kinase

Bioorganic & Medicinal Chemistry Letters
2007.0

Abstract

This communication details the evolution of the screening lead SB-203580, a known CSBP/p38 kinase inhibitor, into a potent and selective Tie2 tyrosine kinase inhibitor. The optimized compound 5 showed efficacy in an in vivo model of angiogenesis and a MOPC-315 plasmacytoma xenograft model.

Knowledge Graph

Similar Paper

Pyridinylimidazole inhibitors of Tie2 kinase
Bioorganic & Medicinal Chemistry Letters 2007.0
1-Substituted 4-Aryl-5-pyridinylimidazoles:  A New Class of Cytokine Suppressive Drugs with Low 5-Lipoxygenase and Cyclooxygenase Inhibitory Potency
Journal of Medicinal Chemistry 1996.0
Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases
Bioorganic & Medicinal Chemistry Letters 2008.0
Tri-substituted imidazole analogues of SB203580 as inducers for cardiomyogenesis of human embryonic stem cells
Bioorganic & Medicinal Chemistry Letters 2013.0
Design, Synthesis, and Biological Evaluation of 3,4-Diarylmaleimides as Angiogenesis Inhibitors
Journal of Medicinal Chemistry 2006.0
Discovery of novel anti-angiogenesis agents. Part 10: Multi-target inhibitors of VEGFR-2, Tie-2 and EphB4 incorporated with 1,2,3-triazol
European Journal of Medicinal Chemistry 2019.0
Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation
Bioorganic & Medicinal Chemistry Letters 2006.0
Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
Bioorganic & Medicinal Chemistry Letters 2006.0
Discovery of 4-amino-2-(thio)phenol derivatives as novel protein kinase and angiogenesis inhibitors for the treatment of cancer: Synthesis and biological evaluation. Part II
European Journal of Medicinal Chemistry 2013.0
Identification and SAR of a new series of thieno[3,2-d]pyrimidines as Tpl2 kinase inhibitors
Bioorganic & Medicinal Chemistry Letters 2011.0